Imaging services provider Medical Resources of Hackensack, NJ, was delisted last month from the NASDAQ stock exchange. Medical Resources’ common stock was delisted on April 22 when NASDAQ advised the company that it does not conform to the
Imaging services provider Medical Resources of Hackensack, NJ, was delisted last month from the NASDAQ stock exchange. Medical Resources common stock was delisted on April 22 when NASDAQ advised the company that it does not conform to the requirements for listing on either the NASDAQ National Market or the NASDAQ SmallCap Market. The company believes its stock may be eligible for trading on NASDAQs OTC Bulletin Board. Medical Resources has the right to appeal NASDAQs decision.
The news paints a bleak picture of the status of Medical Resources business. In March, the company hired investment banking firm BT Alex. Brown of New York City and announced that it would seek an acquisition partner (SCAN 3/31/99). It also reported mediocre results for 1998 (end-December), posting a net loss of $19.9 million. The company attributed the loss to charges related to doubtful accounts receivable and charges associated with the settlement of a class-action lawsuit.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.